|1.||Callies, Sophie: 6 articles (11/2014 - 12/2010)|
|2.||Lahn, Michael: 5 articles (11/2014 - 12/2010)|
|3.||André, Valérie: 4 articles (11/2014 - 12/2010)|
|4.||Talbot, Denis C: 4 articles (01/2012 - 12/2010)|
|5.||Brandt, John T: 2 articles (08/2013 - 02/2011)|
|6.||Kadam, Sunil: 2 articles (08/2013 - 12/2010)|
|7.||McHugh, Peter J: 2 articles (01/2012 - 12/2010)|
|8.||Olsen, Anna L: 2 articles (01/2012 - 12/2010)|
|9.||Ranson, Malcolm: 2 articles (01/2011 - 12/2010)|
|10.||Saleem, Azeem: 2 articles (01/2011 - 12/2010)|
08/01/2011 - "Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors."
01/01/2011 - "Following radiolabeling of LY2181308 with methylated carbon-11 ([(11)C]methylated-LY2181308), micro-doses (<1mg) were administered to three patients with solid tumors enrolled in a phase I trial. "
12/15/2010 - "Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study."
12/01/2010 - "The aim of the study was to develop a rapid and reproducible method to label LY2181308, an antisense oligonucleotide to Survivin, with carbon-11 in order to study its in vivo biodistribution and tumor uptake in rodents and its human dosimetry based on baboon data. "
01/01/2012 - "Focusing upon the survivin protein, and its depletion by an antisense oligonucleotide (ASO) (LY2181308), we show that we can robustly identify a subpopulation of survivin positive tumor cells in FOB samples, and, moreover, detect survivin depletion in tumor samples from a patient treated with LY2181308. "
|2.||Prostatic Neoplasms (Prostate Cancer)
02/01/2011 - "On the basis of these, LY2181308 is being evaluated in a clinical setting (Phase II) in combination with docetaxel for the treatment of prostate cancer."
03/01/2014 - "A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer."
|3.||Melanoma (Melanoma, Malignant)
02/01/2011 - "A 57-year-old man with metastatic melanoma was treated with the survivin inhibitor and antisense oligonucleotide LY2181308 as part of a First-in-Human Dose trial. "
02/01/2011 - "Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma."
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/01/2014 - "To investigate whether blocking survivin expression enhances docetaxel-induced apoptosis in patients with non-small-cell lung cancer (NSCLC), we compared the antitumor activity of the survivin inhibitor LY2181308 plus docetaxel with docetaxel alone. "
11/01/2014 - "Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study."
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
|4.||Messenger RNA (mRNA)
|5.||Caspase 3 (Caspase-3)
|7.||Idarubicin (4 Demethoxydaunorubicin)
|2.||Heterologous Transplantation (Xenotransplantation)